form of Protein A are manufactured in Sweden; recombinant forms of Protein A are manufactured in both the United States and Sweden; assembly of the OPUS chromatography product line is done in the United States. The lease on the main Waltham facility extends through 2023. A second, smaller Waltham facility was leased through the end of 2012 and is now rented on a monthly basis. In Lund, four buildings are under lease, three expiring in mid-2017 and the fourth extending to late 2019. Corporate history and governance Alexander Rich was a co-founder of Repligen; in 2014 at the age of 87, Dr. Rich is "Chairman Emeritus".of Repligen's Board of Directors. Dr. Rich had been a member of the Board since 1981. Paul Schimmel is also a co-founder of Repligen; in 2014 at the age of 74, he is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He used to be the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT. , the company's President and Chief Executive Officer is Tony J. Hunt. Acquisitions and in-licensing In early 2010, Repligen licensed technology from BioFlash which it subsequently incorporated into the OPUS line of pre-packaged chromatography columns. In 2011, Repligen acquired bioproduction assets from Novozymes for $26.4 million, which doubled the company's bioprocessing capabilities. In December 2016 the company acquired TangenX for $39 million Divestments and out-licensing In 2008, an agreement was struck to divest certain intellectual property rights to Bristol-Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of 2013. At the end of 2012, Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG3039, to Pfizer. This divestment included licensing rights to two patents to Pfizer.,, At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for and future milestone and royalty payments., Terminations and moth-balling Development of an imaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by the USFDA for additional safety and efficacy data beyond that provided in a New Drug Application (NDA) submission; a Marketing Authorization Application had been submitted in parallel to the EMA. Products and services Repligen is a major supplier of Protein